Results 171 to 180 of about 43,170 (263)

ERRATUM: Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction. [PDF]

open access: yesJ Endocrinol
Apaijai N   +4 more
europepmc   +1 more source

Insulin Efsitora Demonstrates Similar Efficacy and Safety Profiles to Insulin Icodec in Insulin‐Experienced Individuals With Type 2 Diabetes Mellitus: Matching‐Adjusted Indirect Comparisons of QWINT‐3 Versus ONWARDS 2, and QWINT‐4 Versus ONWARDS 4

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10725-10735, November 2026.
ABSTRACT Aims To conduct indirect treatment comparisons (ITCs) of insulin efsitora alfa (efsitora) versus insulin icodec (icodec) in insulin‐experienced individuals with Type 2 Diabetes Mellitus. Methods Efficacy, safety and patient reported outcomes were compared via matching‐adjusted ITCs using results from randomised controlled trials: QWINT‐3 ...
Harpreet S. Bajaj   +8 more
wiley   +1 more source

Exploratory Analysis of Type 2 Diabetes Mellitus Metabolic Phenotypes and Their Association With Vitamin D Status in Primary Care Patients

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10603-10614, November 2026.
ABSTRACT Aims This study aimed to perform an exploratory characterisation of metabolic phenotypes in primary care patients with type 2 diabetes mellitus (T2DM), using a predefined approach and examine their association with vitamin D status. Materials and Methods This cross‐sectional study included 178 participants randomly selected in Sergipe, Brazil.
Liliane Viana Pires   +10 more
wiley   +1 more source

SGLT‐2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

open access: yesEuropean Journal of Haematology, Volume 117, Issue 5, Page 1347-1357, November 2026.
ABSTRACT Aims We aimed to investigate drug response of sodium‐glucose transport protein‐2 inhibitors (SGLT2i) in multiple myeloma (MM), as SGLT2i have potential favorable effects on conditions related to MM. Methods We conducted a pharmacoepidemiologic study with a US nationwide health insurance claim data using Cox models to investigate the ...
Enze Liu   +6 more
wiley   +1 more source

Immune Consequences of Metabolic Syndrome and Its Treatment: A Cytokine Perspective

open access: yesImmunology, Volume 179, Issue 3, Page 390-405, November 2026.
Peripheral blood mononuclear cells (PBMCs) from individuals with metabolic syndrome (MetS) who were not using glucose‐and/or lipid lowering medication (GLLM) exhibited a broader cytokine production profile after in vitro antigen‐specific stimulation than PBMCs from individuals with MetS using such medications and from healthy donors.
Isabela Ghetti Macedo Isaac   +7 more
wiley   +1 more source

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms

open access: yesObesity Reviews, Volume 27, Issue 11, November 2026.
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy